{
    "nctId": "NCT00201864",
    "briefTitle": "Exemestane in Combination With Fulvestrant in Postmenopausal Women With Hormone Sensitive Advanced Breast Cancer",
    "officialTitle": "Phase II Trial of Exemestane (Aromasin) in Combination With Fulvestrant (Faslodex) in Postmenopausal Women With Hormone Sensitive Advanced Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 40,
    "primaryOutcomeMeasure": "Time to Progression (TTP) in Women With Hormone Responsive Advanced Breast Cancer Treated With Combination of Exemestane and Fulvestrant.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Proven breast cancer\n* Metastatic or locally advanced breast cancer\n* Hormonally responsive disease defined as estrogen (ER) and/ or progesterone receptor (PR) positive (\\>10% staining by immunohistochemistry)\n* Postmenopausal status\n* No more than 1 prior chemotherapy for stage IV metastatic breast cancer allowed\n* ECOG (Eastern Cooperative Oncology Group) performance status 0-2\n* Adequate organ function\n* Exclusion Criteria:\n* No prior Exemestane or Fulvestrant\n* Uncontrolled intercurrent illness including but not limited to:\n\n  * ongoing or active infection\n  * symptomatic congestive heart failure\n  * unstable angina pectoris\n  * cardiac arrhythmia\n  * myocardial infarction within the last 3 months\n  * psychiatric illness/social situations that would limit compliance with study\n* Lymphangitic pulmonary disease; carcinomatous meningitis, bone marrow only metastases; and a rising tumor marker without any other site of metastatic disease.\n* Presence of bleeding diathesis or coagulopathy, patients requiring coumadin",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}